Discovery of Natural Product Derived Labdane Appended Triazoles as Potent Pancreatic Lipase Inhibitors

Renjitha Jalaja,^{†,||} Shyni G. Leela,[‡] Praveen K. Valmiki,^{†,||} Chettiyan Thodi F. Salfeena,^{†,||} Kizhakkan T. Ashitha,^{†,||} Venkata Rao D. Krishna Rao,[§] Mangalam S. Nair,[†] Raghu K. Gopalan,^{*,†,||} and Sasidhar B. Somappa^{*,†,||}

[†]Chemical Sciences and Technology Division, CSIR - National Institute for Interdisciplinary Science and Technology (CSIR-NIIST), Thiruvananthapuram - 695 019, Kerala, India

[‡]Agro-Processing and Technology Division, CSIR-NIIST, Thiruvananthapuram - 695 019, Kerala, India

[§]CSIR - Central Institute of Medicinal and Aromatic Plants, Research Centre, Bangalore - 560065, Karnataka, India

^{||}Academy of Scientific and Innovative Research (AcSIR), CSIR-NIIST, Thiruvananthapuram - 695 019, Kerala, India

S Supporting Information

ABSTRACT: Obesity contributes to the genesis of many metabolic disorders including dyslipidemia, coronary heart disease (CHD), nonalcoholic fatty liver, type 2 diabetes, etc. Pancreatic lipase plays a vital role in food fat digestion and absorption. Therefore, to control obesity, inhibition of pancreatic lipase is the active therapy. Thus, novel natural product derived labdane appended triazoles with pancreatic lipase inhibition potential were designed and synthesized. Among these hybrids, **6b** and **6f** exhibited excellent inhibitory activity (IC_{50} $0.75 \pm 0.02 \mu M$ and $0.77 \pm 0.01 \mu M$), slightly better than that of the positive control Orlistat (IC_{50} $0.8 \pm 0.03 \mu M$). Compounds **6c**, **6e**, and **6g–j** inhibited the PL comparable to that of positive control. Interestingly none of the compounds showed cytotoxicity (Hep G2) in the concentration range from 0.5 to 100 μM . Overall results reveal the potential of labdane appended triazoles as antiobesity agents.

KEYWORDS: Zingiberaceae, *curcuma amada*, triazoles, pancreatic lipase inhibition, obesity related disorders

Obesity is a medical condition with excess body fat accumulation to the extent which leads to serious health consequences. Obesity contributes to the genesis of many metabolic disorders, including dyslipidemia,¹ coronary heart disease (CHD),² nonalcoholic fatty liver,³ type 2 diabetes,⁴ etc. In 2017 WHO reported that global obesity has almost tripled since 1975.⁵ As per literature, more than 340 million children and adolescents between 5 and 19 aged are overweight or obese.⁵ As a result, physicians are prompted to take aggressive treatments in lifestyle changes, pharmacological interventions, and surgical therapies before a severe consequence becomes clinically apparent. Among these various treatments, pharmacotherapy is the most commonly used one.^{6,7}

Pancreatic lipase plays a vital role in food fat digestion and absorption.⁸ Therefore, to control obesity, inhibition of pancreatic lipase enzyme is the active therapy. Among the existing medicines, Orlistat is one such precise drug used for the inhibition of pancreatic lipase. In recent times, natural/herbal products have also been considered as an alternative medicine for the treatment of obesity and related disorders.^{9,10} Many plant-based extracts have been reported for the treatment of obesity and associated diseases. For instance, ethanolic extracts of *Terminalia paniculata* showed very good

antilipase and antiobesity activities.¹¹ Likewise, some terpenoid saponins from the leaves of *Acantho panaxenticosus*,¹² the phenolic acids from fermented oats,¹³ apple polyphenols,¹⁴ and flavan-3-ol digalate esters of oolong tea are found to have substantial pancreatic lipase inhibitory properties.¹⁵

Based on the traditional applications and its large medicinal properties in a long history of Ayurvedic medicine, we have selected *Curcuma amada* Roxb. for the exploration of its inhibition properties against the pancreatic lipase. *C. amada*, an edible ginger is one of the rhizomatous species in the Zingiberaceae family. The rhizomes of *C. amada* are a rich source of essential oils, and more than 130 phytochemicals are isolated,¹⁶ which possess various biological properties, viz. antimicrobial, antioxidant, anti-inflammatory, anticancer, cardiovascular, and gastrointestinal disorders, etc.^{16–19}

Therefore, in continuation of our focused ongoing research interest in natural products and natural product based lead molecule^{20–22} identification for therapeutic applications, in the present work, we have isolated the major compound (E)-

Received: March 6, 2018

Accepted: June 18, 2018

Published: June 18, 2018

Labda-8(17),12-diene-15,16-dial. This was synthetically transformed to rationally designed triazole appended analogues and evaluated for their pancreatic lipase inhibitory potential. The rationale for the targeted synthesis of triazole appended analogues is based upon its broad spectrum of biological properties.^{23,24} Triazole and pyrazole based synthetic drugs are also well-known for the treatment of obesity and related disorders (Figure 1).^{25–27} To begin with, the fresh rhizomes of

Figure 1. Rationale for the synthesis of labdane appended triazoles.

C. amada were collected from CTCRI, Thiruvananthapuram, India, in February 2017. By following a standard protocol (Supporting Information) compound **1** (*E*)-labda 8(17), 12-diene-15,16-dial was isolated from the chloroform extract as a colorless solid and confirmed by using various spectroscopic data: IR, ¹H NMR, ¹³C NMR, HRMS, etc.^{19,28} A series of variously substituted triazole appended labdane derivatives were prepared by a three-step protocol starting from compound **1**. When subjected to Jone's oxidation, one of the aldehydes of compound **1** is selectively oxidized into the acid derivative, Zerumin A (**2**). The alkyne intermediate (**3**) of Zerumin A is prepared in excellent yields by treating **2** with propargyl bromide (Scheme 1). The propargylated labdane

Scheme 1. Synthesis of Propargylated Labdane (**3**) and Substituted Benzyl and Phenacylazides (**5a–q**)

undergoes the click reaction with various substituted benzyl and phenacyl azides (**5**) at room temperature to provide 1,2,3-triazole appended labdane derivatives (**6a–q**) in good to excellent yields (Scheme 2). All the synthesized derivatives are fully characterized by IR, NMR, and HRMS spectral data (Supporting Information).

The isolated *E*-labda-8(17),12-diene-15,16-dial (**1**), semi-synthetic intermediates, and targeted triazole appendages were evaluated for the inhibitory activity against pancreatic lipase (PL) (Method A)²⁹ (Supporting Information). The parent molecule labdane dial exhibited moderate activity. Among those tested, the majority of the triazole hybrids showed strong PL inhibitory activity in the concentration ranging from 0.75 to 14.63 μ M. Initially, the percentage of enzyme inhibition of

Scheme 2. Synthesis of Labdane Appended Triazoles by Click Chemistry (**6a–q**)

compounds at various concentrations (1, 5, 10, and 20 μ M) was evaluated. At lower concentration of 1 μ M, compounds **6b** and **6f** showed inhibition of 75 to 80%. At 20 μ M concentration the derivatives **6b**, **6c**, **6e**, **6f**, **6g**, **6h**, and **6j** exhibited maximum inhibition percentage of 80 to 85 (Figure 2). The other compounds (**6a**, **6k**, **6l**, **6m**, and **6q**) also

Figure 2. Percentage inhibition of isolates and synthetic derivatives against pancreatic lipase in various concentrations.

showed better tendency to inhibit the PL. In contrast, few derivatives (**6d**, **6i**, **6n**, **6o**, and **6p**) failed to show any significant effect on pancreatic lipase. Overall, the labdane-triazole hybrids inhibited the PL through a concentration dependent manner.

Isolates and synthetic derivatives are tested at concentrations 1–20 μ M. Each experiment was independently performed four times in duplicate and expressed as mean $\pm$ SD ($n = 4$).

In an attempt to validate the potential of the compounds, the PL inhibitory activity was repeated using human pancreatic lipase (Method B)³⁰ (Supporting Information). As expected, the compounds followed the similar trend in exhibiting the

inhibitory potential with IC_{50} values in the range of 1.10–14.48 μM concentration. The derivatives **6b**, **6c**, **6g**, and **6h** presented maximum PL inhibition percentage of 80 to 85 at 15 μM concentration (Figure 3). Similarly, triazole analogues **6d**,

Figure 3. Percentage of isolates and synthetic derivatives against human pancreatic lipase in various concentrations.

6i, **6n**, **6o**, and **6p** have failed to inhibit the human pancreatic lipase. The IC_{50} values of active compounds with maximum inhibitory potential are calculated and summarized in Table 1.

Table 1. 50% Inhibitory Concentration (IC_{50}) Evaluation of Labdane Appended Triazoles

Compound	IC_{50} (μM) ^a	
	Method A	Method B
1	14.63 $\pm$ 0.11	14.48 $\pm$ 0.51
2	10.30 $\pm$ 2.71	11.75 $\pm$ 0.64
3	8.64 $\pm$ 3.13	7.38 $\pm$ 0.77
6a	5.35 $\pm$ 1.20	9.15 $\pm$ 0.27
6b	0.75 $\pm$ 0.02	1.1 $\pm$ 0.53
6c	0.85 $\pm$ 0.03	2.01 $\pm$ 0.73
6e	0.80 $\pm$ 0.05	1.65 $\pm$ 0.93
6f	0.77 $\pm$ 0.01	1.25 $\pm$ 0.78
6g	0.91 $\pm$ 0.02	2.28 $\pm$ 0.88
6h	0.95 $\pm$ 0.02	2.31 $\pm$ 0.62
6j	0.84 $\pm$ 0.07	1.87 $\pm$ 0.14
6k	4.43 $\pm$ 1.02	6.90 $\pm$ 0.73
6l	10.36 $\pm$ 2.20	13.48 $\pm$ 0.53
6m	6.22 $\pm$ 2.04	7.82 $\pm$ 0.48
Orlistat	0.80 $\pm$ 0.03	0.19 $\pm$ 0.62

^aThe IC_{50} values of PL inhibitory activity for selected compounds and the positive control Orlistat. Values are mean $\pm$ SD of four independent experiments performed in duplicates.

The IC_{50} results revealed (Method A) that the labdane triazole appendages **6b** and **6f** exhibited an excellent inhibitory activity with $0.75 \pm 0.02 \mu\text{M}$ and $0.77 \pm 0.01 \mu\text{M}$, respectively, which is slightly better than that of positive control Orlistat (IC_{50} $0.8 \pm 0.03 \mu\text{M}$). Compounds **6c**, **6e**, and **6g–j** inhibited the pancreatic lipase comparable to that of positive control in the range IC_{50} 0.8 to 0.9 μM , whereas, the parent molecule **1**, semisynthetic intermediates **2** and **3**, and labdane triazole derivatives **6a**, **6k**, **6l**, and **6m** showed moderate potency in the range of IC_{50} 5.35–14.63 μM . However, against the human

pancreatic lipase (Method B), labdane triazole appendages **6b** and **6f** being the more potent analogues exhibited the inhibitory activities with IC_{50} values $1.1 \pm 0.53 \mu\text{M}$ and $1.25 \pm 0.78 \mu\text{M}$, respectively. Compounds **6c**, **6e**, and **6g–j** also showed promising ability in inhibiting the PL with IC_{50} values in the range of 1.65 to 2.31 μM . The parent molecule and other derivatives showed moderate activity. The preliminary studies also revealed that the compounds are bound to the active site of PL and probably exhibited a covalent interaction with PL. Nevertheless, extended kinetics and crystallographic studies are to be conducted for further authentication of a mode of interaction. We believe this is the first report on the pancreatic lipase inhibitory activity of labdane dial and its semisynthetic triazole appendages.

Isolates and synthetic derivatives are tested at concentrations 0.5–15 μM . Each experiment was independently performed four times in duplicate and expressed as means $\pm$ SD ($n = 4$).

From a structure–activity relationship point of view, we observed that the labdane-triazole hybrids incorporating benzyl azides (**6a–l**) were more active than the phenacyl azides (**6m–q**). Most of the analogues synthesized from benzyl azides exhibited excellent inhibition properties, slightly better than or equal to that of Orlistat. In contrast, the triazole analogues synthesized from phenacyl azides (**6m–q**) did not show any significant inhibition potential except for compound **6m**. Precisely, among the triazoles incorporated from the variously substituted benzyl azides, all the para-substituted analogues showed the lowest IC_{50} . However, the unsubstituted (**6a**), ortho- and meta-substituted benzyl azide incorporated triazole appendages showed moderate activity. Interestingly, there was no clear trend followed by the nature of the para substitution, i.e., among the halogen, electron donating, and electron withdrawing groups. Overall, among the various substituted hybrids **6b** and **6f** with *p*-F and *p*-Cl substituted benzyl azide incorporated triazole appendages were found to be the most potent candidates of the series.

Molecular docking studies have also been performed³¹ in the present study to understand the basic knowledge on how these compounds have blocked human pancreatic lipase activity. There were 20 compounds docked on human pancreatic lipase to understand their possible binding site with respect to the binding energies of structure conformations of compounds (Figure 4; Figure S, Supporting Information). The top ranked stable structure conformations on protein have shown the least Gibb's free binding energies. The docking results have shown that all the triazole derivatives are able to interact with lipase at the possible predicted site with different binding energies (Table S; Supporting Information). However, further experimental studies (i.e., site directed mutagenesis) are much

Figure 4. Representative molecular docking studies of compound **6e**.

needed to understand the precise mechanism of action of these compounds. This data provided us a vital clue about the interaction sites, which helps in our future in-depth studies toward lipase inhibition.

Further, in vitro toxicity of isolated and semisynthetic derivatives is carried out to analyze the effect of compounds on human liver cell lines. This method is primarily used to identify potentially hazardous compounds and their toxic effect in the early stage of development of therapeutic drugs. The cytotoxicity of compounds on Hep G2 human liver carcinoma-derived cell lines was measured by MTT assay.³² The cytotoxic effect of each compound was estimated by calculating the percentage of cell viability in a dose-dependent manner ranging from 0.5 μ M to 100 μ M (Figure 5). Based on

Figure 5. Cytotoxic study of isolates and selected semisynthetic derivatives by MTT assay.

the percentage of cell viability, compounds **6a**, **6c**, **6f**, **6g**, **6h**, **6j**, **6k**, and **6q** were found to be the least toxic on Hep G2 human liver cell lines, and none of the compounds showed any signs of toxicity at all the tested concentrations.

The cytotoxic effect of each compound is expressed as percentage of cell viability in a dose dependent manner. Values are mean $\pm$ SD of four independent experiments performed in duplicates.

In summary, a new series of natural product derived labdane-triazole hybrids were designed, synthesized, and evaluated for pancreatic lipase inhibitory potential. Among the semisynthetic derivatives, **6b** and **6f** are the most active candidates of the series with excellent PL inhibitory activity slightly higher than that of the positive control Orlistat. Hybrids **6c**, **6e**, and **6g–j** inhibited the PL comparable to that of positive control. The structure–activity relationship studies suggested that the *p*-substitution on benzyl azides seems to be vital for improved PL inhibition. Cytotoxicity of the compounds on Hep G2 human liver carcinoma-derived cell line was measured by MTT assay. Based on the percentage of cell viability, none of the compounds showed any signs of toxicity at all the tested concentrations. This is the first report on the PL inhibitory activity of labdane dial and its semisynthetic triazole appendages. Our findings will provide useful insights for the design and synthesis of novel PL inhibitors. Presently, a detailed study to elucidate the molecular mechanistic action of an antiobesity effect of the

compounds **6b** and **6f** by using in vitro and in vivo experimental models and structural optimization is in progress in our laboratory.

■ ASSOCIATED CONTENT

§ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchemlett.8b00109.

Experimental details of synthesis, pancreatic lipase activity assay, MTT assay, molecular docking studies, characterization data, and copies of ¹H and ¹³C NMR spectra of all the newly synthesized compounds (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

*Raghu K. Gopalan E-mail: raghukgopal@niist.res.in.

*Sasidhar B. Somappa E-mail: drsasidharbs@niist.res.in.

ORCID

Sasidhar B. Somappa: 0000-0003-1546-2083

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

Financial support from the DST-Science & Engineering Research Board (SERB), Government of India, New Delhi, India, (Grant no.EEQ/2016/000089) is gratefully acknowledged. R.J. and P.K.V. thank CSIR and UGC for research fellowships. S.G.L acknowledges Young Scientist Fellowship from Department of Health Research (DHR-HRD).

■ REFERENCES

- (1) Barnes, A. Overweight versus Obese: Different Risk and Different Management. *Tex Heart Inst. J.* **2015**, *42*, 237–238.
- (2) Donahue, R. P.; Abbott, R. D.; Bloom, E.; Reed, D. M.; Yano, K. Central Obesity and Coronary Heart Disease in Men. *Lancet* **1987**, *329*, 821–824.
- (3) Fabbri, E.; Sullivan, S.; Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. *Hepatology* **2010**, *51*, 679–89.
- (4) Golay, A.; Ybarra, J. Link between obesity and type 2 diabetes. *Best Pract. Res. Clin. Endocrinol. Metab.* **2005**, *19*, 649–63.
- (5) Obesity facts from: <http://www.who.int/mediacentre/factsheets/fs311/en/index.html>.
- (6) Fu, C.; Jiang, Y.; Guo, J.; Su, Z. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. *J. Agric. Food Chem.* **2016**, *64*, 9571–9585.
- (7) Cosentino, G.; Conrad, A. O.; Uwaifo, G. I. Phentermine and topiramate for the management of obesity: a review. *Drug Des., Dev. Ther.* **2013**, *7*, 267–278.
- (8) Wang, T. Y.; Liu, M.; Portincasa, P.; Wang, D. Q. New insights into the molecular mechanism of intestinal fatty acid absorption. *Eur. J. Clin. Invest.* **2013**, *43*, 1203–23.
- (9) Sun, N. N.; Wu, T. Y.; Chau, C. F. Natural Dietary and Herbal Products in Anti-Obesity Treatment. *Molecules* **2016**, *21*, 1351.
- (10) Fu, C.; Jiang, Y.; Guo, J.; Su, Z. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. *J. Agric. Food Chem.* **2016**, *64*, 9571–9585.
- (11) Mopuri, R.; Meriga, B. Anti-Lipase and Anti-Obesity Activities of *Terminalia paniculata* Bark in High Calorie Diet-Induced Obese Rats. *Global J. Pharmacol.* **2014**, *8*, 114–119.
- (12) Jiang, W.; Li, W.; Han, L.; Liu, L.; Zhang, Q.; Zhang, S.; Nikaido, T.; Koike, K. Biologically Active Triterpenoid Saponins from *Acanthopanax senticosus*. *J. Nat. Prod.* **2006**, *69*, 1577–1581.

- (13) Cai, S.; Wang, O.; Wang, M.; He, J.; Wang, Y.; Zhang, D.; Zhou, F.; Ji, B. In Vitro Inhibitory Effect on Pancreatic Lipase Activity of Sub fractions from Ethanol Extracts of Fermented Oats (*Avena sativa* L.) and Synergistic Effect of Three Phenolic Acids. *J. Agric. Food Chem.* **2012**, *60*, 7245–7251.
- (14) Sugiyama, H.; Akazome, Y.; Shoji, T.; Yamaguchi, A.; Yasue, M.; Kanda, T.; Ohtake, Y. Oligomeric Procyanidins in Apple Polyphenol Are Main Active Components for Inhibition of Pancreatic Lipase and Triglyceride Absorption. *J. Agric. Food Chem.* **2007**, *55*, 4604–4609.
- (15) Nakai, M.; Fukui, Y.; Asami, S.; Toyoda-Ono, Y.; Iwashita, T.; Shibata, H.; Mitsunaga, T.; Hashimoto, F.; Kiso, Y. Inhibitory Effects of Oolong Tea Polyphenols on Pancreatic Lipase in Vitro. *J. Agric. Food Chem.* **2005**, *53*, 4593–4598.
- (16) Jatoi, S. A.; Kikuchi, A.; Gilani, S. A.; Watanabe, K. N. Phytochemical, Pharmacological and Ethnobotanical Studies in Mango Ginger. *Phytother. Res.* **2007**, *21*, 507–516.
- (17) Behera, K. K. Ethnomedicinal Plants used by the Tribals of Similipal Bio-reserve, Orissa, India: A Pilot Study. *Ethnobotanical Leaflets* **2006**, *10*, 149–173.
- (18) Ramachandran, C.; Quirin, K. W.; Escalon, E. A.; Lollett, I. V.; Melnick, S. J. Therapeutic Effect of Supercritical CO₂ Extracts of Curcuma Species with Cancer Drugs in Rhabdomyosarcoma Cell Lines. *Phytother. Res.* **2015**, *29*, 1152–1160.
- (19) Singh, S.; Kumar, J. K.; Saikia, D.; Shanker, K.; Thakur, J. P.; Negi, A. S.; Banerjee, S. A bioactive labdane diterpenoid from *Curcuma amada* and its semi-synthetic analogues as antitubercular agents. *Eur. J. Med. Chem.* **2010**, *45*, 4379–4382.
- (20) Shilpa, G.; Renjitha, J.; Saranga, R.; Sajin, K. F.; Nair, M. S.; Joy, B.; Sasidhar, B. S.; Priya, S. Epoxyazadiradione Purified from the *Azadirachta indica* Seed Induced Mitochondrial Apoptosis and Inhibition of NF κ B Nuclear Translocation in Human Cervical Cancer Cells. *Phytother. Res.* **2017**, *31*, 1892–1902.
- (21) Kumar, V. P.; Renjitha, J.; Salfeena, C. T. F.; Ashitha, K. T.; Keri, R. S.; Varughese, S.; Sasidhar, B. S. Antibacterial and antitubercular evaluation of dihydronaphthalenone-indole hybrid analogs. *Chem. Biol. Drug Des.* **2017**, *90*, 703–708.
- (22) Ashitha, K. T.; Kumar, V. P.; Salfeena, C. T. F.; Sasidhar, B. S. BF₃·OEt₂-Mediated Tandem Annulation: A Strategy To Construct Functionalized Chromeno- and Pyrano-Fused Pyridines. *J. Org. Chem.* **2018**, *83*, 113–124.
- (23) Narsimha, S.; Battula, K. S.; Nukala, S. K.; Gondru, R.; Reddy, Y. N.; Nagavelli, V. R. One-pot synthesis of fused benzoxazino[1,2,3] triazolyl[4,5-c]quinolinone derivatives and their anticancer activity. *RSC Adv.* **2016**, *6*, 74332.
- (24) Tantray, M. A.; Khan, I.; Hamid, H.; Alam, M. S.; Umar, S.; Ali, Y.; Sharma, K.; Hussain, F. Synthesis of Novel Oxazolo[4,5-b]pyridine-2-one based 1,2,3-triazoles as Glycogen Synthase Kinase-3 β Inhibitors with Anti-inflammatory Potential. *Chem. Biol. Drug Des.* **2016**, *87*, 918–926.
- (25) Kharb, R.; Sharma, P. C.; Yar, M. S. Pharmacological significance of triazole scaffold. *J. Enzyme Inhib. Med. Chem.* **2011**, *26*, 1–21.
- (26) Kinf, H. H.; Belay, Y. H.; Joseph, J. S.; Mukwevho, E. Evaluation of the Influence of thiosemicarbazone–triazole hybrids on genes implicated in lipid oxidation and accumulation as potential anti-obesity agents. *Bioorg. Med. Chem. Lett.* **2013**, *23*, 5275–5278.
- (27) Sharma, M. K.; Machhi, J.; Murumkar, P.; Yadav, M. R. New role of phenothiazine derivatives as peripherally acting CB1 receptor antagonizing anti-obesity agents. *Sci. Rep.* **2018**, *8*, 1650.
- (28) Sheeja, A. D. B.; Nair, M. S. Facile isolation of *E*-labda 8(17), 12-diene-15, 16-dial from curcuma amada and its conversion to other biologically active compounds. *Indian J. Chem. Sect. B* **2014**, *53*, 319–324.
- (29) Bustanji, Y.; Issa, A.; Mohammad, M.; Hudaib, M.; Tawah, K. Inhibition of hormone sensitive lipase and pancreatic lipase by *Rosmarinus officinalis* extract and selected phenolic constituents. *J. Med. Plants Res.* **2010**, *4*, 2235–2242.
- (30) Kido, Y.; Hiramoto, S.; Murao, M.; Horio, Y.; Miyazaki, T.; Kodama, T.; Nakabou, Y. Epsilon-polylysine inhibits pancreatic lipase activity and suppresses postprandial hypertriglyceridemia in rats. *J. Nutr.* **2003**, *133*, 1887–91.
- (31) Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. *J. Comput. Chem.* **1998**, *19*, 1639–1662.
- (32) Wilson, A. P. Cytotoxicity and viability assay. In *Animal cell culture: A practical approach*, 2nd ed.; Masters JRW, Oxford University Press: Oxford, 2000; pp 175–219.